AWT-020

N/A

Report date: 2026/05/09 20:00:18

Base Information

Drug NameAWT-020
Drug Alias NameMableukin 2PD1AWT020AWT-020JS213JS-213
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-2 receptor subunit gamma stimulantsInterleukin-2 receptor beta chain stimulantsAnti-PD-1
TargetsInterleukin-2 receptor subunit gammaInterleukin-2 receptor beta chainProgrammed cell death protein 1
Therapy Area/IndicationsSolid tumoursAutoimmune Diseases of the Nervous SystemCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAnwita Biosciences Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAnwita Biosciences IncShanghai Junshi Biosciences Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursAutoimmune Diseases of the Nervous SystemCarcinoma, Non-Small-Cell Lung +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A